Revisiting Monoamine Oxidase Inhibitors
J Clin Psychiatry 2007;68(suppl 8):35-41
© Copyright 2017 Physicians Postgraduate Press, Inc.
Access to this article is available to valid users
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Register: If you do not have one already, register for a free account.
Monoamine oxidase inhibitors (MAOIs) were among the first class of agents introduced for the treatment
of depression. However, they have fallen out of favor among clinicians over the years, due mostly to an unfavorable
safety profile, the need for restrictive dietary prohibitions, and the fear of hypertensive crisis. The
development of a novel, transdermal MAOI system now offers clinicians an additional option for managing
patients with unipolar, bipolar, atypical, and treatment-resistant depression.